U.S. Markets closed

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
87.14+0.86 (+1.00%)
Al cierre: 04:00PM EST
86.00 -1.14 (-1.31%)
Fuera de horario: 04:10PM EST

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700

Empleados a tiempo completo3,401

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Brian R. MuellerCFO & Executive VP1.15M1.09M1974
Mr. George Eric DavisExecutive VP, Chief Legal Officer, General Counsel & Secretary1.23M2.11M1971
Mr. Jeffrey Robert AjerExecutive VP & Chief Commercial Officer1.18MN/D1962
Dr. Henry J. Fuchs M.D., Ph.D.President of Worldwide Research & Development1.49MN/D1958
Mr. Alexander HardyPresident, CEO & DirectorN/DN/D1969
Ms. Erin BurkhartGroup VP & Chief Accounting OfficerN/DN/DN/D
Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentN/DN/DN/D
Traci McCartyGroup Vice President of Investor RelationsN/DN/DN/D
Ms. Humaira SerajuddinSenior VP & Chief Marketing OfficerN/DN/DN/D
Ms. Amy WiremanExecutive VP & Chief People OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Gestión corporativa

La calificación ISS Governance QuickScore de BioMarin Pharmaceutical Inc. a partir del 28 de febrero de 2024 es 4. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 5; Compensación: 5.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.